Impact of IPX203 on Parkinson’s patients’ motor states upon awakening: analysis of patient diary data
Objective: To evaluate “On” upon awakening in Parkinson’s disease patients taking IPX203 in the RISE-PD phase 3 clinical trial. Background: IPX203 is a novel extended-release,…The HIIT-Home4Parkinson’s study
Objective: This study aims to evaluate the practicality and utility of a novel, co-created home-based high-intensity interval training (HIIT) programme for people with Parkinson’s (PwP).…Interim results of a mixed method research-in-action study to evaluate and improve patient and public involvement within the EJS ACT-PD initiative
Objective: To improve patient and public involvement and engagement (PPIE) within EJS ACT-PD by evaluating members’ perceptions of PPIE through a mixed methods research-in-action study.…Predictability of Motor States With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease
Objective: To assess predictability of “On” or “Off” motor states in patients (pts) with advanced Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa (LDp/CDp). Background: Pts with…Patient Experiences Initiating Continuous Subcutaneous Apomorphine Infusion (CSAI): An Interview-Based Survey of InfusON Study Participants
Objective: Obtain patient feedback on experiences initiating and using continuous subcutaneous apomorphine infusion (CSAI). Background: Previously reported data from the ongoing InfusON study demonstrated that…Effect of the mGlu2 positive allosteric modulator biphenyl-indanone A on parkinsonian disability in the 6-hydroxydopamine-lesioned rat
Objective: To evaluate the effect of biphenyl-indanone A (BINA), a metabotropic glutamate 2 (mGlu2) receptor positive allosteric modulator (PAM), on parkinsonian disability in the 6-OHDA-lesioned…Targeting miR-27 with Antisense Oligonucleotides for Disease Modification in Parkinson’s Disease
Objective: Achieve disease modification in idiopathic Parkinson’s Disease through miR-27 targeting using Antisense Oligonucleotides Background: There are currently no disease-modifying therapies for Parkinson’s Disease (PD).…Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
Objective: We sought to determine whether fecal bile acids (BAs) could affect levodopa response assessed by levodopa challenge test (LCT) in patients with Parkinson’s disease…A Preliminary Report on the Clinical Profile of People with PD at an Outpatient Clinic in Malawi
Objective: The objective of the study is to analyze the clinical and socio-demographic characteristics of people with Parkinson`s (PwP) attending the adult neurology outpatient clinic…Pharmacokinetics of Levodopa after Subcutaneous bolus delivery of foslevodopa/foscarbidopa
Objective: To characterize the pharmacokinetics (PK) of levodopa (LD) after bolus delivery of foslevodopa/foscarbidopa Background: Foslevodopa/foscarbidopa is a soluble formulation of LD/CD prodrugs delivered as…
- « Previous Page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- …
- 181
- Next Page »